2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 158.144 | 170.591 | 195.301 | 221.331 | 219.562 | 207.584 | 194.531 | 217.356 | 289.125 | 199.922 |
Total Income - EUR | 158.145 | 170.591 | 195.301 | 221.331 | 219.562 | 207.584 | 194.531 | 217.356 | 289.125 | 199.922 |
Total Expenses - EUR | 156.533 | 169.019 | 191.420 | 219.171 | 218.112 | 202.111 | 190.953 | 212.865 | 310.289 | 202.225 |
Gross Profit/Loss - EUR | 1.611 | 1.572 | 3.881 | 2.161 | 1.451 | 5.473 | 3.579 | 4.491 | -21.164 | -2.303 |
Net Profit/Loss - EUR | 1.611 | 1.572 | 3.881 | 2.161 | 986 | 3.397 | 1.768 | 2.544 | -24.059 | -2.303 |
Employees | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Lupexim Comed Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Assets | 19.927 | 21.805 | 22.330 | 24.179 | 24.421 | 36.401 | 69.292 | 108.759 | 86.721 | 88.548 |
Inventories | 18.588 | 19.989 | 20.472 | 21.069 | 22.982 | 35.341 | 65.045 | 99.091 | 70.649 | 79.487 |
Receivables | 109 | 537 | 14 | 14 | 113 | 437 | 4.100 | 8.343 | 13.114 | 668 |
Cash | 1.229 | 1.279 | 1.845 | 3.096 | 1.327 | 623 | 147 | 1.325 | 2.958 | 8.393 |
Shareholders Funds | -13.504 | -12.045 | -8.041 | 4.001 | 4.914 | 8.216 | 9.828 | 12.154 | -11.868 | -14.134 |
Social Capital | 107 | 108 | 107 | 9.851 | 9.670 | 9.483 | 9.303 | 9.097 | 9.125 | 9.097 |
Debts | 33.431 | 33.850 | 30.371 | 20.177 | 19.507 | 28.185 | 59.464 | 96.605 | 98.589 | 102.682 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4719 - 4719" | |||||||||
CAEN Financial Year |
4719
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Lupexim Comed Srl